Search NTRR
NEUTRA CORP.
OTC · CIK 1512886
Last close0
Daily change+0.00 (0.00%)
10 Years gain-99.96%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
NTRR · STANDARD
SIC 2833 · Medicinal Chemicals & Botanical Products · Fiscal year end 0131
Fundamental
32.9Momentum
0.0Acceleration
0.0Confidence
68.0Annual Revenue4
Quarterly Revenue15
Annual CFO13
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth17.3 / 25
Quality8.1 / 25
Capital Efficiency0.0 / 20
Balance Sheet5.8 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 16.9493 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Operating margin compression · MEDIUMOperating margin compressed by 164.0567 percentage points.
Low interest coverage · HIGHInterest coverage is -14.3803x.
Key Metrics
Revenue Growth TTM-56.84%OK
Revenue CAGR 3Y119.89%OK
Gross Margin45.18%OK
Operating Margin-750.92%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFO0.02xOK
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 FY Jan 31, 2023 | $67,996.00 | $35,306.00 | -$297,675.00 | -$153,243.00 | n/a | 51.92% | -437.78% | n/a | n/a | n/a |
| 2023 FY Jan 31, 2022 | $92,014.00 | $31,161.00 | -$583,582.00 | -$405,615.00 | -$445,842.00 | 33.87% | -634.23% | -484.54% | n/a | n/a |
| 2022 FY Jan 31, 2021 | $9,687.00 | -$33,257.00 | -$478,665.00 | -$412,378.00 | -$608,868.00 | -343.32% | -4,941.31% | -6,285.41% | n/a | n/a |
| 2021 FY Jan 31, 2020 | $6,395.00 | $6,395.00 | -$394,245.00 | -$181,607.00 | n/a | 100% | -6,164.89% | n/a | n/a | n/a |
| 2020 FY Jan 31, 2019 | n/a | n/a | -$1.71M | -$417,000.00 | n/a | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $34,861.00 | sum latest 4 fiscal quarters Revenue | OK | 0001161697-23-000627, 0001161697-23-000369 |
| Revenue Growth TTM | -56.84% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001161697-23-000627, 0001161697-23-000369 |
| Revenue CAGR 3Y | 119.89% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001161697-23-000341 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001161697-23-000341 |
| Gross Profit CAGR 3Y | 76.74% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001161697-23-000341 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001161697-23-000627, 0001161697-23-000369 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 45.18% | Gross Profit / Revenue | OK | 0001161697-23-000627, 0001161697-23-000369 |
| Operating Margin | -750.92% | Operating Income / Revenue | OK | 0001161697-23-000627, 0001161697-23-000369 |
| Net Debt / CFO | 0.02x | Net Debt / CFO | OK | 0001161697-23-000627, 0001161697-23-000485 |
| Interest Coverage | -14.38x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 0.02x | Current Assets / Current Liabilities | OK | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001161697-23-000341 |